Q1 2026 · 13F-HR
Decheng Capital LLCholdings as filed
Filed 2026-05-13 · accession 0001104659-26-060145
$661.3M
Reported value
14
Positions
2026-03-31
Period end
The Brief · Decheng Capital LLC · Q1 2026
AI · grounded in 13F
Decheng Capital LLC closed its entire position in Crinetics Pharmaceuticals CRNX, reducing its holdings by $4.3M. The fund also trimmed several other positions, most notably reducing share counts in Krystal Biotech KRYS by 57.8% and Revolution Medicines RVMD by 53.3%. In total, the fund reduced 10 of its 14 positions and added no new holdings.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $431.2M | 65.2% | 6,371,669 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio Inc. | $111.3M | 16.8% | 25,954,439 | Common | SOLE |
| 91678A107 | UPB | Upstream Bio Inc. | $24.5M | 3.71% | 2,724,868 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $15.2M | 2.29% | 4,041,736 | Common | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $14.8M | 2.23% | 3,917,299 | Common | SOLE |
| 55083R104 | LYEL | Lyell Immunopharma, Inc. | $13.9M | 2.10% | 692,050 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $10.4M | 1.57% | 325,057 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences, Inc | $10.3M | 1.56% | 477,819 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC(NSM) | $9.1M | 1.37% | 93,500 | Common | SOLE |
| 29446K106 | EQ | Equillium Inc. | $8.9M | 1.34% | 4,447,308 | Common | SOLE |
| G10830100 | BYSI | BeyondSpring Inc. | $6.2M | 0.94% | 3,800,702 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals Inc. | $3.1M | 0.47% | 1,323,327 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $1.9M | 0.29% | 7,300 | Common | SOLE |
| 747324101 | PYXS | Pyxis Oncology, Inc (formerly Apexigen) | $477,143 | 0.07% | 326,810 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.